-
11.发明申请公开(公告)号：US20110119484A1
公开(公告)日：2011-05-19
申请号：US12616493
申请日：2009-11-11
Applicant: Ramsey Jallad , Patrick Stach , John Terrill , Gary Bartholomew , Lyndon Paul Wright , Paul Anton Sop
Inventor： Ramsey Jallad , Patrick Stach , John Terrill , Gary Bartholomew , Lyndon Paul Wright , Paul Anton Sop
CPC classification number: H04L63/123 , H04L63/0823 , H04L63/166 , H04L67/02
Abstract: The invention is directed to a system for use with a first device in communication with a second device. The system includes a storage medium that is connectable with the first device, a hardened, stand alone, web browser stored on the storage medium, and client authentication data. The web browser uses the client authentication data to facilitate secure communication between the first device and the second device, and the first device communicates with a third device that provides configuration data that includes one or more approved addresses.
Abstract translation: 本发明涉及一种与第二设备通信的第一设备一起使用的系统。 该系统包括可与第一设备连接的存储介质，存储在存储介质上的硬化，独立的web浏览器和客户端认证数据。 网络浏览器使用客户端认证数据来促进第一设备和第二设备之间的安全通信，并且第一设备与提供包括一个或多个批准地址的配置数据的第三设备进行通信。
-
公开(公告)号：US20100102926A1
公开(公告)日：2010-04-29
申请号：US12530813
申请日：2008-03-13
Applicant: Bruce Donaldson Grieve , Paul Wright , Peter Green
Inventor： Bruce Donaldson Grieve , Paul Wright , Peter Green
IPC: G05B19/00
CPC classification number: H04Q9/00 , H04Q2209/43 , H04Q2209/883
Abstract: Methods and systems are provided for controlling a first node in an ad hoc network including network nodes, at least some of which are asynchronous nodes having a dormancy period and a non-dormancy period. The method may include activating a non-dormant-state after a predetermined period of dormancy. The method may also include storing status information at the first node, said status information describing at least one condition of the first node. The method may also include receiving, during the non-dormant-state, status information about a second, non dormant node. The method may also include storing the received status information at the first node. The method may also include communicating the stored status information of the first node and the second node and reactivating the dormant-state.
Abstract translation: 提供了用于控制包括网络节点的自组织网络中的第一节点的方法和系统，其中至少一些是具有休眠时段和非休眠时段的异步节点。 该方法可以包括在预定的休眠期之后激活非休眠状态。 该方法还可以包括在第一节点处存储状态信息，所述状态信息描述第一节点的至少一个条件。 该方法还可以包括在非休眠状态期间接收关于第二非休眠节点的状态信息。 该方法还可以包括将接收到的状态信息存储在第一节点处。 所述方法还可以包括传送所存储的第一节点和第二节点的状态信息并重新激活休眠状态。
-
公开(公告)号：USD535353S1
公开(公告)日：2007-01-16
申请号：US29257157
申请日：2006-03-30
Applicant: Paul Wright , Ian McCoy
Designer： Paul Wright , Ian McCoy
-
公开(公告)号：US20060003993A1
公开(公告)日：2006-01-05
申请号：US10495464
申请日：2002-11-12
Applicant: Iain McDonald , Ildiko Buck , Elaine Harper , Ian Linney , Michael Pether , Katherine Steel , Carol Austin , David Dunstone , Sarkis Kalindjian , Caroline Low , John Spencer , Paul Wright
Inventor： Iain McDonald , Ildiko Buck , Elaine Harper , Ian Linney , Michael Pether , Katherine Steel , Carol Austin , David Dunstone , Sarkis Kalindjian , Caroline Low , John Spencer , Paul Wright
IPC: A61K31/5513
CPC classification number: C07D401/04 , A61K31/4439 , A61K31/545 , A61K31/55 , C07D255/00 , Y02P20/582 , A61K2300/00
Abstract: This invention relates to a compound of formula (I) wherein: W is N or N+—O−; and R1 to R5 are as defined in the description, for use for the treatment of gastrin related disorders.
Abstract translation: 本发明涉及式（I）的化合物，其中：W是N或N + - O - R 1至R 5如在描述中所定义，用于治疗胃泌素相关病症。
-
公开(公告)号：US2260926A
公开(公告)日：1941-10-28
申请号：US30568339
申请日：1939-11-22
Applicant: PAUL WRIGHT
Inventor： PAUL WRIGHT
CPC classification number: G01F13/001 , F23K3/00 , F23K2203/002
-
Patent Agency Ranking
公开(公告)号：US1859858A
公开(公告)日：1932-05-24
申请号：US40304829
申请日：1929-10-28
Applicant: PAUL WRIGHT
Inventor： PAUL WRIGHT
IPC: F22B21/04
CPC classification number: F22B21/04
-
![Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel](/abs-image/US/2016/04/05/US09303035B2/abs.jpg.150x150.jpg)
17.发明授权Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel 有权取代的吡嗪并[1'，2'：1,2]吡咯并[3,4-d]嘧啶，嘧啶并[4'，5'：3,4]吡咯并[2,1-c] [1,4] 嘧啶并[4'，5'：3,4]吡咯并[1,2-d] [1,4]氧氮杂用于抑制CFTR通道公开(公告)号：US09303035B2
公开(公告)日：2016-04-05
申请号：US14109927
申请日：2013-12-17
Applicant: Mahbub Ahmed , Alexander Ashall-Kelly , Graham Charles Bloomfield , Louisa Gueritz , Jeffrey McKenna , Joseph McKenna , Simon Mutton , Rakesh Parmar , Jon Sheperd , Paul Wright
Inventor： Mahbub Ahmed , Alexander Ashall-Kelly , Graham Charles Bloomfield , Louisa Gueritz , Jeffrey McKenna , Joseph McKenna , Simon Mutton , Rakesh Parmar , Jon Sheperd , Paul Wright
IPC: A61K31/519 , C07D239/70 , C07D487/14 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D498/14
CPC classification number: C07D487/14 , A61K31/519 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D498/14
Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 本发明提供式I化合物或其药学上可接受的盐; 及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号：US20140171417A1
公开(公告)日：2014-06-19
申请号：US14109922
申请日：2013-12-17
Applicant: Mahbub AHMED , Alexander ASHALL-KELLY , Louisa GUERITZ , Jeffrey MCKENNA , Joseph MCKENNA , Simon MUTTON , Rakesh PARMAR , Jon SHEPHERD , Paul WRIGHT
Inventor： Mahbub AHMED , Alexander ASHALL-KELLY , Louisa GUERITZ , Jeffrey MCKENNA , Joseph MCKENNA , Simon MUTTON , Rakesh PARMAR , Jon SHEPHERD , Paul WRIGHT
IPC: C07D513/00 , C07D471/14 , A61K45/06 , C07D487/14 , A61K31/55 , A61K31/542 , A61K31/519
CPC classification number: C07D513/14 , A61K31/519 , A61K31/542 , A61K31/55 , A61K45/06 , C07D471/14 , C07D487/04 , C07D487/14 , C07D487/22 , C07D495/14 , C07D513/00
Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20140171412A1
公开(公告)日：2014-06-19
申请号：US14109927
申请日：2013-12-17
Applicant: Mahbub AHMED , Alexander ASHALL-KELLY , Graham Charles BLOOMFIELD , Louisa GUERITZ , Jeffrey MCKENNA , Joseph MCKENNA , Simon MUTTON , Rakesh PARMAR , Jon SHEPERD , Paul WRIGHT
Inventor： Mahbub AHMED , Alexander ASHALL-KELLY , Graham Charles BLOOMFIELD , Louisa GUERITZ , Jeffrey MCKENNA , Joseph MCKENNA , Simon MUTTON , Rakesh PARMAR , Jon SHEPERD , Paul WRIGHT
IPC: C07D487/14 , A61K45/06 , A61K31/5383 , A61K31/553 , A61K31/519 , C07D498/14
CPC classification number: C07D487/14 , A61K31/519 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D498/14
Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 本发明提供式I化合物或其药学上可接受的盐; 及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号：USD647195S1
公开(公告)日：2011-10-18
申请号：US29359326
申请日：2010-04-08
Applicant: Roger William Clarke , Matthew Paul Wright , Mike Paul Sheldon , Oliver Taylor Harvey
Designer： Roger William Clarke , Matthew Paul Wright , Mike Paul Sheldon , Oliver Taylor Harvey
-
-
-
-
-
-
-
-
-
Search Results
60
records
(took 0.025 seconds)
